TABLE 3.
Supportive care interventions and medications
| Variablea | Value(s) for: |
|
|---|---|---|
| IFN group (n = 42) | Control group (n = 39) | |
| Time from starting symptoms to start of interventions (means ± SD) | 11.70 ± 5.71 | 9.31 ± 4.45 |
| ICU admission, n (%) | 19 (45.23) | 23 (58.97) |
| Respiratory support, n (%) | ||
| Nasal cannula | 2 (4.76) | 1 (2.56) |
| Face mask | 24 (57.14) | 21 (53.84) |
| NIPPV | 1 (2.38) | 0 |
| IMV | 15 (35.71) | 17 (43.58) |
| Medications, n (%) | ||
| Hydroxychloroquine | 40 (95.23) | 39 (100.0) |
| Antiviral regimen | 42 (100) | 39 (100) |
| Atazanavir-ritonavir | 17 (40.47) | 19 (48.71) |
| Lopinavir-ritonavir | 25 (59.52) | 20 (51.28) |
| Azithromycin | 8 (19.04) | 5 (12.82) |
| Vitamin C | 13 (30.95) | 12 (30.76) |
| Broad-spectrum antibiotics | 33 (78.57) | 27 (69.23) |
| Diphenhydramine | 17 (40.47) | 26 (66.66) |
| Antiemetic | 11 (26.19) | 6 (15.38) |
| Opioid | 14 (33.33) | 17 (43.58) |
| Stress ulcer prophylaxis | 42 (100) | 39 (100) |
| Deep-vein thrombosis prophylaxis | 41 (97.61) | 37 (94.87) |
| Statins | 9 (21.42) | 6 (15.38) |
| ARBs | 10 (23.80) | 4 (10.25) |
| Beta-blockers | 8 (19.04) | 2 (5.12) |
| Calcium channel blockers | 7 (16.66) | 5 (12.82) |
| ACEIs | 1 (2.38) | 2 (5.12) |
| Corticosteroid | 26 (61.90) | 17 (43.58) |
| Immunoglobulin | 15 (35.71) | 10 (25.64) |
a
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; IMV, invasive mechanical ventilation; NIPPV, noninvasive positive pressure ventilation; SD, standard deviations.